New Tufts CSDD Analysis Finds AI Agents Can Deliver Up to $21 Million in Net Financial Value Per Drug Development Program and Up to 82x ROI
PALO ALTO, Calif. — Medable Inc., the leading technology platform for agentic clinical development, today announced a new Tufts Center for the Study of Drug Development (CSDD) analysis showing that an AI clinical monitoring agent can deliver net financial gains as high as $21 million per drug development program and 82 times the return on […]
We haven't written up this one. Financial Post has the full story — the link below goes straight to it.
